New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
16:00 EDTFB, AAPL, GILD, TSLA, DGOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
News For TSLA;AAPL;DG;GILD;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 16, 2015
08:53 EDTFBFacebook to buy Pebbles for about $60M, WSJ reports
Subscribe for More Information
08:34 EDTAAPLSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
08:18 EDTAAPLSeveral stocks attractive following Intel results, says JMP Securities
For investors looking to take advantage of the sentiment shift the Intel (INTC) results could mean for the group and stronger demand due to seasonality and the Windows 10 launch, JMP Securities recommends Nvidia (NVDA) and Micron (MU). The firm says that both stocks have more attractive valuations and "more strategic roadmaps" than Intel. It also recommends Apple (AAPL) and Qualcomm (QCOM) as more attractive and secure dividend growth plays.
08:14 EDTFBFacebook faces foreign exchange headwinds in Q2, says Brean Capital
Subscribe for More Information
07:22 EDTAAPLiPhone average selling prices may be underestimated by Street, says UBS
Subscribe for More Information
07:19 EDTAAPLApple Q3 iPhone estimates raised at Stifel
Subscribe for More Information
06:58 EDTAAPLApple applies for patent for wireless devices with solar cells
Subscribe for More Information
06:46 EDTAAPLApple Watch to roll out in New Zealand July 31, AppleInsider reports
Subscribe for More Information
July 15, 2015
16:00 EDTFB, AAPLOptions Update; July 15, 2015
Subscribe for More Information
12:38 EDTAAPLGundlach says out of Apple position
Subscribe for More Information
11:01 EDTAAPLApple introduces new iPod touch, unveils new colors for iPod models
Subscribe for More Information
09:53 EDTAAPLHSBC UK says Apple Pay support coming within 2 weeks, Apple Insider says
HSBC UK (HSBC) said that Apple Pay (AAPL) support is in its final testing and availability will be coming within two weeks, reports Apple Insider. An HSBC spokesperson said, "We are excited to be one of a small number of Apple Pay launch partners. We have been working closely with Apple and are now properly reviewing and testing our systems before launching in two weeks." Reference Link
09:32 EDTAAPL, FBActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
09:18 EDTFBAdobe's Flash disabled by Google due to security worries, WSJ says
Just days after Facebook's (FB) top security executive called on Adobe (ADBE) to discontinue its Flash animation player, Google’s (GOOG) Chrome and Mozilla’s Firefox browsers blocked old versions of the software on Tuesday after reports that hackers were using a security flaw to infiltrate computers, reported The Wall Street Journal's "Digits" blog. Firefox and Chrome will allow Flash to run again if it is updated with the patch Adobe released Tuesday morning, the report noted. Reference Link
08:33 EDTFBFacebook target raised to $110 at Morgan Stanley on mobile ad strength
Morgan Stanley raised 2015 and 2016 revenue estimates for Facebook and increased its price target on the shares to $110 due to scale and improving products. The firm's mobile ad checks indicate Facebook is still the mobile industry leader, has low pricing and high ad ROI, and continues to pull in a larger share of ad budgets and ad dollars per MAU. Morgan Stanley has an Overweight rating on shares of the social network owner, which closed yesterday at $89.68.
08:27 EDTFBAdobe says Google display ad strategy underperforms Facebook in Q2
In its "Digital Advertising & Social Intelligence Report" for Q2, Adobe (ADBE) wrote that Facebook's (FB) display ad changes doubled its click-through-rates, or CTRs, year-over-year in the quarter, while Google's (GOOG) display targeting changes reduced its number of ads seen by 22% compared to the prior year and its CTRs were up "only" 24% compared to the same period of last year. The report also contends that the "Mobilegeddon" fears regarding Google's changes to favor mobile friendly sites came true, noting that sites with low mobile engagement saw up to a 10% decrease in organic traffic after the changes were made by the search giant. Reference Link
07:58 EDTGILDAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
06:39 EDTAAPLApple to release new iPod touch, 9to5Mac reports
Subscribe for More Information
06:33 EDTAAPLApple 'in touch' with Iranian distributors to sell products there, WSJ reports
Subscribe for More Information
06:32 EDTTSLATesla buys 2,000 extra acres for Nevada factory, WSJ reports
Tesla has almost tripled its land holdings in Nevada recently, having bought nearly 2,000 additional acres near Reno as it works on a factory intended to build batteries for electric cars and stationary backup batteries, the Wall Street Journal reports. Tesla originally bought 1,000 acres last year, though that agreement including options to purchase additional land, the report says. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use